NCT03321656View on ClinicalTrials.gov

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

78

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

End Stage Renal Disease

Interventions

DRUG

Tacrolimus

0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally

DRUG

Envarsus XR

0.07-0.14 mg/kg/day every morning orally

Trial Locations (1)

40536

RECRUITING

Deepa Valvi, Lexington

Sponsors

Collaborators (1)

Veloxis Pharmaceuticals

All Listed Sponsors

collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

Roberto Gedaly

OTHER

NCT03321656 - Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | Biotech Hunter | Biotech Hunter